These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 33485454)

  • 1. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.
    Mingrone G; Panunzi S; De Gaetano A; Guidone C; Iaconelli A; Capristo E; Chamseddine G; Bornstein SR; Rubino F
    Lancet; 2021 Jan; 397(10271):293-304. PubMed ID: 33485454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.
    Mingrone G; Panunzi S; De Gaetano A; Guidone C; Iaconelli A; Nanni G; Castagneto M; Bornstein S; Rubino F
    Lancet; 2015 Sep; 386(9997):964-73. PubMed ID: 26369473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bariatric surgery versus conventional medical therapy for type 2 diabetes.
    Mingrone G; Panunzi S; De Gaetano A; Guidone C; Iaconelli A; Leccesi L; Nanni G; Pomp A; Castagneto M; Ghirlanda G; Rubino F
    N Engl J Med; 2012 Apr; 366(17):1577-85. PubMed ID: 22449317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial.
    Ikramuddin S; Billington CJ; Lee WJ; Bantle JP; Thomas AJ; Connett JE; Leslie DB; Inabnet WB; Jeffery RW; Chong K; Chuang LM; Sarr MG; Jensen MD; Vella A; Ahmed L; Belani K; Schone JL; Olofson AE; Bainbridge HA; Laqua PS; Wang Q; Korner J
    Lancet Diabetes Endocrinol; 2015 Jun; 3(6):413-422. PubMed ID: 25979364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic intestinal bypass surgery for type 2 diabetes in patients with a BMI <35 kg/m2: comparative analysis of 16 patients undergoing either BPD, BPD-DS, or RYGB.
    Frenken M; Cho EY
    Obes Facts; 2011; 4 Suppl 1(Suppl 1):13-7. PubMed ID: 22027284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Verrastro O; Panunzi S; Castagneto-Gissey L; De Gaetano A; Lembo E; Capristo E; Guidone C; Angelini G; Pennestrì F; Sessa L; Vecchio FM; Riccardi L; Zocco MA; Boskoski I; Casella-Mariolo JR; Marini P; Pompili M; Casella G; Fiori E; Rubino F; Bornstein SR; Raffaelli M; Mingrone G
    Lancet; 2023 May; 401(10390):1786-1797. PubMed ID: 37088093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial.
    Hofsø D; Fatima F; Borgeraas H; Birkeland KI; Gulseth HL; Hertel JK; Johnson LK; Lindberg M; Nordstrand N; Cvancarova Småstuen M; Stefanovski D; Svanevik M; Gretland Valderhaug T; Sandbu R; Hjelmesæth J
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):912-924. PubMed ID: 31678062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study.
    Madsen LR; Baggesen LM; Richelsen B; Thomsen RW
    Diabetologia; 2019 Apr; 62(4):611-620. PubMed ID: 30734055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roux-en-Y Gastric Bypass Versus Medical Treatment for Type 2 Diabetes Mellitus in Obese Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yan Y; Sha Y; Yao G; Wang S; Kong F; Liu H; Zhang G; Zhang H; Hu C; Zhang X
    Medicine (Baltimore); 2016 Apr; 95(17):e3462. PubMed ID: 27124041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of type 2 diabetes relapse after Roux-en-Y Gastric Bypass: A ten-year follow-up study.
    Moriconi D; Manca ML; Anselmino M; Rebelos E; Bellini R; Taddei S; Ferrannini E; Nannipieri M
    Diabetes Metab; 2022 Jan; 48(1):101282. PubMed ID: 34547450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects and safety of Roux-en-Y gastric bypass surgery vs. conventional medication in obese Chinese patients with type 2 diabetes.
    Feng W; Yin T; Chu X; Shan X; Jiang C; Wang Y; Qian Y; Zhu D; Sun X; Bi Y
    Diabetes Metab Res Rev; 2019 Jul; 35(5):e3138. PubMed ID: 30740871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roux-en-Y gastric bypass versus best medical treatment for type 2 diabetes mellitus in adults with body mass index between 27 and 32 kg/m
    Cheng A; Yeoh E; Moh A; Low S; Tan CH; Lam B; Sum CF; Subramaniam T; Lim SC
    Diabetes Res Clin Pract; 2022 Jun; 188():109900. PubMed ID: 35513159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial.
    Cummings DE; Arterburn DE; Westbrook EO; Kuzma JN; Stewart SD; Chan CP; Bock SN; Landers JT; Kratz M; Foster-Schubert KE; Flum DR
    Diabetologia; 2016 May; 59(5):945-53. PubMed ID: 26983924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial.
    Robert M; Espalieu P; Pelascini E; Caiazzo R; Sterkers A; Khamphommala L; Poghosyan T; Chevallier JM; Malherbe V; Chouillard E; Reche F; Torcivia A; Maucort-Boulch D; Bin-Dorel S; Langlois-Jacques C; Delaunay D; Pattou F; Disse E
    Lancet; 2019 Mar; 393(10178):1299-1309. PubMed ID: 30851879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Differences in Remission of Type 2 Diabetes Mellitus After Roux-en-Y Gastric Bypass Surgery-Subgroup Analysis of 2-Year Results of the Diabetes Surgery Study Comparing Taiwanese with Americans with Mild Obesity (BMI 30-35 kg/m
    Chong K; Ikramuddin S; Lee WJ; Billington CJ; Bantle JP; Wang Q; Thomas AJ; Connett JE; Leslie DB; Inabnet WB; Jeffery RW; Sarr MG; Jensen MD; Vella A; Ahmed L; Belani K; Schone JL; Olofson AE; Bainbridge HA; Laqua PS; Korner J; Chuang LM
    Obes Surg; 2017 May; 27(5):1189-1195. PubMed ID: 27783367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery for weight loss in adults.
    Colquitt JL; Pickett K; Loveman E; Frampton GK
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD003641. PubMed ID: 25105982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Remission of Type 2 Diabetes and Patient Survival After Biliopancreatic Diversion with Duodenal Switch.
    Frenken M; Kemmet O; Frenken M; Röhrig I; Fischer L; Hellinger A
    Obes Surg; 2022 Oct; 32(10):3340-3350. PubMed ID: 35939221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial.
    Halperin F; Ding SA; Simonson DC; Panosian J; Goebel-Fabbri A; Wewalka M; Hamdy O; Abrahamson M; Clancy K; Foster K; Lautz D; Vernon A; Goldfine AB
    JAMA Surg; 2014 Jul; 149(7):716-26. PubMed ID: 24899464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Bohula EA; Scirica BM; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Kanevsky E; Murphy SA; Leiter LA; Dwyer JP; Corbalan R; Hamm C; Kaplan L; Nicolau JC; Ophuis TO; Ray KK; Ruda M; Spinar J; Patel T; Miao W; Perdomo C; Francis B; Dhadda S; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
    Lancet; 2018 Nov; 392(10161):2269-2279. PubMed ID: 30293771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.